Treatment
Share your love
Kala Bio’s CHASE trial misses primary endpoint, KPI-012 development discontinued | Ophthalmology Times
(Image Credit: AdobeStock) Kala Bio announced that CHASE (NCT05727878), its phase 2b clinical trial of KPI-012 for persistent corneal epithelial defect (PCED), did not meet its primary endpoint. Additionally, the company noted that the trial failed to show statistical significance…
Q&A: Mark Gillies the outcomes of injecting VEGF inhibitors | Ophthalmology Times
Photo of Mark Gillies at the 2025 EURETINA meeting Mark Gillies, MD, PhD, introduced the Fight Retinal Blindness! Project, a comprehensive registry tracking VEGF inhibitor eye injection outcomes since 2007. Spanning 20 countries with 150 active practitioners, the project uniquely…
Q&A: Harvey Uy on the power of digital images and records | Ophthalmology Times
Photo of Harvey Uy, MD, DPBO, FVRSP, at the 2025 EURETINA meeting Harvey Uy, MD, DPBO, FVRDP, a retina specialist from the Peregrine Eye and Laser Institute in the Philippines, discussed the transformative power of digital image management in ophthalmology.…
Q&A: Marion Munk discusses the phase 2a BETTER study | Ophthalmology Times
Photo of Marion Munk at EURETINA 2025 In her conversation with the Eye Care Network, Marion Munk, MD, PhD, details a promising phase 2a clinical study of ISTH0036, an oligonucleotide antisense drug targeting TGF-β2. Developed to address fibrosis in neovascular…
EyeCon 2025: Adopting an interventional glaucoma mindset with Oluwatosin U. Smith, MD | Ophthalmology Times
At this year’s EyeCon meeting, Oluwatosin U. Smith, MD, of the Glaucoma Associates of Texas, reflected on her dual role—both as an educator and a leader in its development—while delivering a focused presentation on the current state of glaucoma care.…
MacuMira launches first Health Canada-approved device for AMD treatment | Ophthalmology Times
(Image Credit: AdobeStock) Canadian medical device company MacuMira Medical Devices recently introduced the first Health Canada-approved treatment to improve visual function for patients with dry age-related macular degeneration (AMD).1 This new technology, the MacuMira system, is a non-invasive treatment now…
Looking ahead: Ophthalmologists envision a world without the toughest diseases | Ophthalmology Times
As Ophthalmology Times celebrates its 50th anniversary, we took the opportunity to ask a thought-provoking question to some of the field’s leading experts: “In a perfect world, if you could cure one eye disease or condition with the snap of…
Q&A: Boris Stanzel on the use of methotrexate in PVR cases | Ophthalmology Times
Photo of Boris Stanzel, MD, at the 2025 EURETINA meeting Professor Boris Stanzel, MD, presented research on methotrexate’s use in PVR retinal detachment surgery at the 2025 EURETINA congress, which was held in Paris, France. The study of 20 patients…
Luxa Biotechnology announces clinical trial results for treatment of AMD | Ophthalmology Times
(Image credit: ©Alex_Traksel/AdobeStock) Luxa Biotechnology LLC announced results from its phase 1/2a clinical trial titled “Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation in Patients with Dry Age-related Macular Degeneration: Low Dose Clinical Outcomes.”1 The results were published…
Idebenone accepted by FDA for priority review for Leber Hereditary Optic Neuropathy | Ophthalmology Times
(Image Credit: AdobeStock) The US Food and Drug Administration (FDA) has granted Priority Review to Chiesi Global Rare Diseases’ idebenone for Leber Hereditary Optic Neuropathy (LHON) Currently there are no clinically proven therapies for LHON in the US. Idebenone is…